Evidence map›Paper›PMID 35460150›Full record

ArticleJournal of applied clinical medical physics2022

Organ-at-risk dose prediction using a machine learning algorithm: Clinical validation and treatment planning benefit for lung SBRT.

N Patrik Brodin, Leslie Schulte, Christian Velten, William Martin, Sydney Shen, Jin Shen, Amar Basavatia, Nitin Ohri, Madhur K Garg, Colin Carpenter and 1 more

Abstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

N Patrik BrodinInstitute for Onco-Physics, Albert Einstein College of Medicine, Bronx, NY, USA.
Leslie SchulteSiris Medical, Burlingame, CA, USA.
Christian VeltenInstitute for Onco-Physics, Albert Einstein College of Medicine, Bronx, NY, USA.
William MartinDepartment of Radiation Oncology, Montefiore Medical Center, Bronx, NY, USA.
Sydney ShenDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Jin ShenDepartment of Radiation Oncology, Montefiore Medical Center, Bronx, NY, USA.
Amar BasavatiaDepartment of Radiation Oncology, Montefiore Medical Center, Bronx, NY, USA.ORCID https://orcid.org/0000-0003-0589-2653
Nitin OhriInstitute for Onco-Physics, Albert Einstein College of Medicine, Bronx, NY, USA.
Madhur K GargInstitute for Onco-Physics, Albert Einstein College of Medicine, Bronx, NY, USA.
Colin CarpenterSiris Medical, Burlingame, CA, USA.
Wolfgang A ToméInstitute for Onco-Physics, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID https://orcid.org/0000-0003-1586-8091

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo quantify the clinical performance of a machine learning (ML) algorithm for organ-at-risk (OAR) dose prediction for lung stereotactic body radiation therapy (SBRT) and estimate the treatment planning benefit from having upfront access to these dose predictions.

methodsML models were trained using multi-center data consisting of 209 patients previously treated with lung SBRT. Two prescription levels were investigated, 50 Gy in five fractions and 54 Gy in three fractions. Models were generated using a gradient-boosted regression tree algorithm using grid searching with fivefold cross-validation. Twenty patients not included in the training set were used to test OAR dose prediction performance, ten for each prescription. We also performed blinded re-planning based on OAR dose predictions but without access to clinically delivered plans. Differences between predicted and delivered doses were assessed by root-mean square deviation (RMSD), and statistical differences between predicted, delivered, and re-planned doses were evaluated with one-way analysis of variance (ANOVA) tests.

resultsANOVA tests showed no significant differences between predicted, delivered, and replanned OAR doses (all p ≥ 0.36). The RMSD was 2.9, 3.9, 4.3, and 1.7Gy for max dose to the spinal cord, great vessels, heart, and trachea, respectively, for 50 Gy in five fractions. Average improvements of 1.0, 1.4, and 2.0 Gy were seen for spinal cord, esophagus, and trachea max doses in blinded replans compared to clinically delivered plans with 54 Gy in three fractions, and 1.8, 0.7, and 1.5 Gy, respectively, for the esophagus, heart and bronchus max doses with 50 Gy in five fractions. Target coverage was similar with an average PTV V100% of 94.7% for delivered plans compared to 97.3% for blinded re-plans for 50 Gy in five fractions, and respectively 98.4% versus 99.2% for 54 Gy in three fractions.

conclusionThis study validated ML-based OAR dose prediction for lung SBRT, showing potential for improved OAR dose sparing and more consistent plan quality using dose predictions for patient-specific planning guidance.

Indexed as

Lung NeoplasmsRadiosurgeryRadiotherapy, Intensity-ModulatedAlgorithmsHumansLungMachine LearningOrgans at RiskRadiotherapy DosageRadiotherapy Planning, Computer-Assisteddose predictionlung SBRTmachine learning

Identifiers

PMID35460150
PMCPMC9195027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.